Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis

Overview of attention for article published in NEJM Evidence, August 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 6 news outlets
policy: 1 policy source

twitter: 31 X users
facebook: 1 Facebook page

Readers on

mendeley: 49 Mendeley

So far, Altmetric has seen 6 news stories from 6 outlets.

Un régimen más breve contra la tuberculosis no da resultados

Espanol.news, 31 Aug 2023

Los regímenes más cortos de rifampicina en dosis altas resultaron seguros para tratar la tuberculosis pulmonar (TB), pero no…

Eine kürzere TB-Therapie verfehlt das Ziel

Germanic.News, 31 Aug 2023

Kürzere hochdosierte Rifampicin-Therapien erwiesen sich als sicher für die Behandlung von Lungentuberkulose (TB), zeigten…

Shorter TB Regimen Misses the Mark

MedPage Today, 30 Aug 2023

Infectious Disease > Tuberculosis But researchers still see potential for high-dose rifampicin-based treatment strategy by Ian…

Higher dose and shorter tuberculosis treatment proven safe for patients

Opera News, 29 Aug 2023

Kaplan–Meier Time to Unfavorable Outcome for the Primary mITT-M Population. The inset shows the same data on an enlarged y axis.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.